Fragmento

Dear editor: Despite recommendations on the prevention of HBV reactivation in patients receiving immunosuppressive therapy,1 those treated with ≥ 4 weeks of corticosteroids remain at significant risk of HBV reactivation but are frequently overlooked. Here we describe the first two reported cases of HBV reactivation in the context of corticosteroid induced immunosuppression for treatment of IgG4-related disease.

Palabras clave:

2018-08-22   |   140 visitas   |   Evalua este artículo 0 valoraciones

Vol. 17 Núm.1. Enero-Febrero 2018 Pags. 174-175 Ann Hepatol 2018; 17(1)